The protein C anticoagulant pathway provides many new insights into control mechanisms for regulating coagulation. The observation that protein C deficiency is associated with thrombotic tendencies in the heterozygote (106-109) and early, lethal thrombosis in the homozygote (110, 111) points to the importance of the system as a major regulatory pathway. The complexity of the system has only recently begun to emerge. Thrombin activation of protein C at the endothelial cell surface requires not only the synthesis of thrombomodulin but the coupling of the receptor to a protein C binding site. It is reasonable to assume that an inherited or acquired deficiency in thrombomodulin might lead to thrombotic tendencies. This aspect of the system may explain, in part, the association between vascular disease and thrombosis. Once activated, protein C has an almost total dependence on protein S to express anticoagulant activity. (98) This suggests that deficiencies of protein S may also be associated with thrombotic tendencies. Protein S offers an additional intriguing property. Protein S, a regulatory protein of the coagulation system, is found both free and associated with C4BP, a regulatory protein of the complement system. The high affinity, very stable interaction between these components (85) suggests that the interaction is likely to be involved in regulation. (89) The importance of the interaction remains to be demonstrated, but clearly this is a potential direct link between major control proteins of the coagulation and complement system. Clinical studies suggest that protein C and/or thrombomodulin might be effective therapeutically. Certainly, protein C supplementation during the onset of oral anticoagulant therapy would be expected to circumvent the transient rapid decrease in protein C levels that may influence the early effectiveness of oral anticoagulants. (119) In addition to the systems clinical importance, protein C, its activation, and its function offer a variety of intriguing biochemical problems. For instance, how does thrombomodulin alter the specificity of thrombin? What is the protein C binding site on the cell surface, and what role does Factor Va or its degradation products play in the formation and regulation of this site? How does protein S facilitate activated protein C anticoagulant activity and what roles do membrane surfaces play in this system? What role does beta-hydroxyaspartic acid play in protein C activation and function? How does activated protein C influence fibrinolytic activity? The answers to these questions will undoubtedly add to our understanding of the fundamental mechanisms involved in regulating blood coagulation.(ABSTRACT TRUNCATED AT 400 WORDS)
蛋白C抗凝途径为调节凝血的控制机制提供了许多新见解。观察发现,杂合子中蛋白C缺乏与血栓形成倾向相关(106 - 109),而纯合子中则与早期致死性血栓形成相关(110, 111),这表明该系统作为主要调节途径的重要性。该系统的复杂性直到最近才开始显现。内皮细胞表面蛋白C的凝血酶激活不仅需要血栓调节蛋白的合成,还需要受体与蛋白C结合位点的偶联。可以合理推测,血栓调节蛋白的遗传性或获得性缺乏可能导致血栓形成倾向。该系统的这一方面可能部分解释了血管疾病与血栓形成之间的关联。一旦被激活,蛋白C几乎完全依赖蛋白S来发挥抗凝活性。(98)这表明蛋白S缺乏也可能与血栓形成倾向相关。蛋白S具有另一个有趣的特性。蛋白S是凝血系统的调节蛋白,既以游离形式存在,也与补体系统的调节蛋白C4BP结合。这些成分之间高亲和力、非常稳定的相互作用(85)表明这种相互作用可能参与调节。(89)这种相互作用的重要性仍有待证明,但显然这是凝血和补体系统主要控制蛋白之间的潜在直接联系。临床研究表明,蛋白C和/或血栓调节蛋白在治疗上可能有效。当然,在口服抗凝治疗开始时补充蛋白C有望避免蛋白C水平的短暂快速下降,而这可能会影响口服抗凝剂的早期疗效。(119)除了该系统的临床重要性外,蛋白C及其激活和功能还提出了各种有趣的生化问题。例如,血栓调节蛋白如何改变凝血酶的特异性?细胞表面的蛋白C结合位点是什么,因子Va或其降解产物在该位点的形成和调节中起什么作用?蛋白S如何促进活化蛋白C的抗凝活性,膜表面在该系统中起什么作用?β - 羟基天冬氨酸在蛋白C激活和功能中起什么作用?活化蛋白C如何影响纤维蛋白溶解活性?这些问题的答案无疑将增进我们对调节血液凝固基本机制的理解。(摘要截取自400字)